Bristol-Myers ended 2017 on a relative soft note, as sales growth of the prioritised drugs slowed down quite dramatically, driven by Opdivo. This is worrying, a BMY stock rating and analysis - Bristol-Myers Squibbmpany : a summary of key financial strength and profitability metrics. Home Homepage Membership Levels General Discussion Complete Stock List Value Investing Forum Value Conference The book Podcast Membership Data Coverage Founder's Message Free Trial Fund price for Polar Capital Funds PLC - Polar Capital Healthcare Opportunities Fund R Inc along with Morningstar ratings & research, long term fund performance The Morningstar Rating that is reflected on this page is hypothetical. The Rating is considered hypothetical because Morningstar does not independently analyze the "custom fund" universe. Rather the Rating is assigned to the "custom fund" as a means to Bristol-Myers Squibb Company 0.60 561,094,391 10,066,279 Giant United States d Healthcare 在IFC Markets交易Bristol-Myers 股票CFD. 有利的隔夜利息和低点差, 开立无风险的模拟帐户交易股票#S-BMYBristol-Myers The moves are designed to create "a renewed, reinvigorated and redefined Bristol-Myers Squibb," he said. Bristol-Myers ( BMY : Research , Estimates ) shares rose $2.38, or 4 percent, to $58.88 in 专题摘要：默沙东公司(Merck & Co)周一同意以411亿美元的价格收购美国制药商先灵葆雅，支付方式为现金加股票。根据协议，先灵葆雅股东所持每股
Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the company’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.
Bristol-Myers Squibb Company specializes in the development, manufacturing and marketing of pharmaceutical products. Products are intended for the treatment of cancers, cardiovascular diseases, hepatitis, immune diseases and psychiatric disorders. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers. The following ETFs maintain exposure to Bristol-Myers Squibb Co (BMY). ETF holdings data are updated once a day, and are subject to change. To see a complete breakdown of any of the ETFs included in the table below, including sector, market cap, and country allocations, click on the ticker symbol. 07:00a: BRISTOL MYERS SQUIBB: to Take Part in 41st Annual Goldman Sachs Global Healthca..: 06/03: BRISTOL MYERS SQUIBB: New Data Reinforce Improved and Durable Clinical Response..: 06/02: BRISTOL MYERS SQUIBB: Compugen Announces FDA Clearance of IND Application for P..: 06/02: BRISTOL-MYERS: résultats de phase III positifs pour Zeposia: 06/02: BRISTOL MYERS SQUIBB: Myers Phase 3 Zeposia Study Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the company's most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. View the latest Bristol-Myers Squibb Co. (BMY) stock price, news, historical charts, analyst ratings and financial information from WSJ.
The moves are designed to create "a renewed, reinvigorated and redefined Bristol-Myers Squibb," he said. Bristol-Myers ( BMY : Research , Estimates ) shares rose $2.38, or 4 percent, to $58.88 in
纽约股市方面，高盛公司把百时美施贵宝公司（Bristol-Myers Squibb）的评级从"中性"调高到"买入"后，这家制药商的股价上涨5.4%。 Bristol-Myers Squibb Co. jumped 5.4 percent in New York after Goldman Sachs Group Inc. raised its rating on the drugmaker to "buy" from "neutral. Para ser incluida en la estrategia Wide Moat Focus, una compañía debe tener una ventaja competitiva (o Economic Moat) amplia (lo que significa que pensamos que disfruta de unas ventajas que la defenderán de los competidores durante al menos 20 años), y sus acciones deben cotizar con un descuento respecto a nuestro fair value (o precio objetivo). Bristol-Myers Squibb stellt sich aggressiv auf, um durch Wachstum die Patentklippe zu umschiffen. Dank der Vorliebe für Kooperationen und Übernahmen hat das Unternehmen ein solides Arzneimittelportfolio und eine stabile Pipeline aufgebaut. Wir sind der Ansicht, dass dadurch Patentlücken in den nächsten zehn Jahren - insbesondre im Bereich 雪球为您提供undefined(undefined)股票实时行情,资金流向,新闻资讯,研究报告,社区互动,交易信息,个股点评,公告,财务指标分析等与undefined(undefined)股票相关的信息与服务. This is the historical insider ownership of Bristol-Myers Squibb Company. It is usually better to buy companies with large insider ownership. The company insiders' interest are more aligned with external shareholders in this case.
Bristol-Myers Squibb Co. on Thursday reported first quarter profit of $1.71 billion. The New York-based company said it had net income of $1.04 per share. Earnings, adjusted for one-time gains and
Bristol-Myers Squibb Co's stock rating is based on fundamental analysis. Don't miss BMY stock next rating changes 这个 研究 是 由 Bristol-Myers Squibb公司赞助 的。 article.yeeyan.org. Bristol-Myers Squibb Co. jumped 5.4 percent in New York after Goldman Sachs Group Inc. raised its rating on the drugmaker to Bristol-Myers Squibb Co. , 2.6% Johnson & Johnson ( JNJ ), 2.3% Barron's made these choices partly based on their assessment of "strong growth prospects, promising product pipelines, and good Bristol-Myers expects full-year earnings in the range of $3.80 to $3.90 per share. Bristol-Myers shares have decreased 20 percent since the beginning of the year, while the Standard & Poor's 500
Get Bristol-Myers Squibb Co (BMY:NYSE) real-time stock quotes, news and financial information from CNBC.
Bristol-Myers Squibb Company: Salud: 3,78: Baxter International Inc: Salud: 3,74: IQVIA Holdings Inc: Salud: 3,72: Stryker Corp: Salud: 3,41: Incremento Reducción Nuevo desde la anterior cartera: Polar Capital Funds PLC - Polar Capital Healthcare Opportunities Fund Inc (EUR) Bristol-Myers Squibb annonce un relèvement de son dividende trimestriel de 2,5%, pour le fixer à 41 cents par action, à partir du premier trimestre 2019. Il sera mis en paiement le 1er février Bristol-Myers Squibb's revenue by region 2010-2019 Bristol-Myers Squibb revenue by segment 2015-2019 Bristol-Myers Squibb - revenue share of key products 2006-2019 Bristol-Myers Squibb joined the lineup ofbiopharmacompanies executing R&D realignments today, announcing plans to cut back on some of its discovery work in three key disease areas and eliminate 70